CN113069393A - 一种眼霜及其制备方法 - Google Patents
一种眼霜及其制备方法 Download PDFInfo
- Publication number
- CN113069393A CN113069393A CN202010015927.8A CN202010015927A CN113069393A CN 113069393 A CN113069393 A CN 113069393A CN 202010015927 A CN202010015927 A CN 202010015927A CN 113069393 A CN113069393 A CN 113069393A
- Authority
- CN
- China
- Prior art keywords
- eye
- skin
- eye cream
- extract
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 17
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 13
- 235000018102 proteins Nutrition 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 9
- 241000209140 Triticum Species 0.000 claims abstract description 9
- 235000021307 Triticum Nutrition 0.000 claims abstract description 9
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 claims abstract description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011703 D-panthenol Substances 0.000 claims abstract description 5
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 5
- 235000004866 D-panthenol Nutrition 0.000 claims abstract description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract description 5
- 229960003237 betaine Drugs 0.000 claims abstract description 5
- 229960003949 dexpanthenol Drugs 0.000 claims abstract description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 3
- 229960000458 allantoin Drugs 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 9
- -1 polydimethylsiloxane Polymers 0.000 claims description 8
- 241000208681 Hamamelis virginiana Species 0.000 claims description 7
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 6
- 241000157280 Aesculus hippocastanum Species 0.000 claims description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 229930194248 Licoflavone Natural products 0.000 claims description 5
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 4
- 235000010181 horse chestnut Nutrition 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 3
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 229960000735 docosanol Drugs 0.000 claims description 3
- 229930182478 glucoside Natural products 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- 229940047670 sodium acrylate Drugs 0.000 claims description 3
- 229940001941 soy protein Drugs 0.000 claims description 3
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 claims description 2
- 229940031674 laureth-7 Drugs 0.000 claims description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 claims 1
- 244000186892 Aloe vera Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 235000011399 aloe vera Nutrition 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 claims 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims 1
- 229940093767 glabridin Drugs 0.000 claims 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 abstract description 11
- 230000037394 skin elasticity Effects 0.000 abstract description 8
- 235000002673 Dioscorea communis Nutrition 0.000 abstract description 6
- 241000544230 Dioscorea communis Species 0.000 abstract description 6
- 208000035753 Periorbital contusion Diseases 0.000 abstract description 6
- 230000003020 moisturizing effect Effects 0.000 abstract description 6
- 235000014104 aloe vera supplement Nutrition 0.000 abstract description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 4
- 206010030113 Oedema Diseases 0.000 abstract description 4
- 229940045809 horse chestnut seed Drugs 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000004089 microcirculation Effects 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 3
- 102000008186 Collagen Human genes 0.000 abstract description 2
- 108010035532 Collagen Proteins 0.000 abstract description 2
- 230000032683 aging Effects 0.000 abstract description 2
- 229920001436 collagen Polymers 0.000 abstract description 2
- 235000005152 nicotinamide Nutrition 0.000 abstract description 2
- 229960003966 nicotinamide Drugs 0.000 abstract description 2
- 239000011570 nicotinamide Substances 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 241000208680 Hamamelis mollis Species 0.000 abstract 1
- 239000004909 Moisturizer Substances 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 230000001333 moisturizer Effects 0.000 abstract 1
- 230000008591 skin barrier function Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229940118846 witch hazel Drugs 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 36
- 230000000694 effects Effects 0.000 description 16
- 206010040954 Skin wrinkling Diseases 0.000 description 10
- 230000006872 improvement Effects 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种眼霜及其制备方法，所述眼霜以水作为溶剂，透明质酸钠、小分子透明质酸钠复合使用锁水深层渗透，增加皮肤弹性；烟酰胺、甘草黄酮美白保湿抗氧化；以尿囊素、D‑泛醇、甜菜碱、水解大豆蛋白、水解小麦蛋白作为保湿剂，形成保湿性肌肤屏障，促进肌肤胶原蛋白合成；以库拉索芦荟提取物、北美金缕梅提取物、七叶树籽提取物、乙酰基四肽‑5作为皮肤调理剂，改善眼部微循环，紧致祛皱，去黑眼圈，延缓衰老，滋养肌肤。本发明能够帮助眼部肌肤密集保湿、深层滋润，改善浮肿、眼袋和黑眼圈，修护细纹皱纹。
Description
技术领域
本发明涉及化妆品领域，具体涉及一种眼霜及其制备方法。
背景技术
如今的快节奏生活、高强度生活压力、环境污染、网上作业特性等原因，眼部皮肤健康问题 逐渐加重，过度用眼、熬夜等造成眼部周围人员出现黑眼圈、细纹、鱼尾纹、脂肪粒等症状、而随着 年龄的增长，新陈代谢缓慢、皮肤弹性、水分大量流失等现象，最先出现皱纹的位置就是脆弱的眼部 皮肤。
眼部肌肤是人体最薄的肌肤，只有面部皮肤的1/4-1/3厚，所以应对外界变化的能力差，非 常脆弱，弹性也很差，因此更容易受到外界的伤害。易出现细纹，而且还是化妆中拉扯皮肤次数最多 的地方，容易衰老。而且眼周只有肌肉，没有骨骼支撑，眼部皮下组织疏松结缔组织丰富、疏松富有 弹性，在结缔组织纤维结构之间分布的丰富的毛细血管和神经末梢，很容易充血积水而形成血肿或者 水肿。所以相对来说比较容易松弛、也是最容易暴露真实年龄的部位。
眼部没有毛孔、皮脂腺以及汗腺，无法分泌油脂和汗液，也无法形成皮脂膜，眼部的肌肤少 了这种天然的保湿膜，非常容易干燥，时间一长就会产生干纹，并且由于没有毛孔使用产品的吸收能 力相对于面部而言会差很多，所以需要特别的护理，面部的产品不能用在眼部，不仅无法吸收，甚至 还会形成脂肪粒。眼部皮肤的敏感脆弱特性导致其极易产生皱纹、黑眼圈、眼袋等眼部亚健康症状。 眼部皮肤的工作负荷重、易疲劳。劳动强度大，每天每个人平均眨眼超过2万次，易疲劳，也容易出 现松弛问题，还有一部分人群还有喜欢眯、眨、挤、揉眼睛的不好习惯，造成眼部问题加重。眼部循 环差，代谢慢，所以一熬夜就容易毒素淤积堵塞不能及时排出体外，形成黑眼圈，如果是晚上睡觉前 喜欢喝水的伙伴，早上起床后还容易出现眼部的水肿现象。
而人们最先想到的缓解措施之一是使用护肤品-眼霜来改变症状。市面上的眼霜种类繁多， 但是仅部分存在一定效果，大部分产品含有较多化学成分，对肌肤存在一定的刺激性和危害性，可能 衍生形成其他眼部问题。因此，需要一个成分精准、效果显著、绿色安全的产品来满足市场需求，特 提出本发明。
发明内容
本发明综合考虑了眼部细纹、黑眼圈等症状的形成原因，本发明的一个目的是提出一种眼霜， 该眼霜以欧洲七叶树籽提取物，北美金缕梅提取物、乙酰基四肽-5、水解大豆蛋白、水解小麦蛋白、 烟酰胺为去黑眼圈、眼袋、细纹的主要成分，并配以透明质酸钠、小分子透明质酸钠复合使用来为眼 部肌肤锁水的同时深层修复、紧致肌肤，恢复肌肤弹性。本发明的另一个目的是提出上述眼霜的制备 方法。
为了实现上述的第一个目的，本发明采用了以下设计方案：
一种眼霜，该组合物按百分质量比计包括以下的组分：
作为优选，该组合物按质量百分比计包括以下的组分：
作为优选，该组合物按质量百分比计包括以下的组分：
作为在优选所述的欧洲七叶树籽提取物能有效清除细胞膜中水溶性和脂溶性的自由基，并且 能够通过血液循环直接作用于肌底细胞，增强血管壁细胞的代谢功能，增强毛细血管抵抗力，减低毛 细血管通透性，促进炎症病变组织恢复，增加毛细血管的弹性，有效形成保护屏障，有效地预防血管 壁受损及病变，从根本上达到修复皮下毛细血管，恢复毛细血管弹性，增强毛细血管扩张、收缩能力， 从而达到祛除红血丝的效果。七叶皂甙能抑制胶原蛋白酶、透明质酸酶和弹性蛋白酶等与血管和肌肤 的纹理和完整性密切相关的破坏酶，促进微循环，改善血管通透性。
作为在优选所述的乙酰基四肽-5通过抑制血管紧张素I转换酶，来改善眼部肌肤的微循环； 增加SOD的活性，抑制其糖基化，阻止蛋白交联，改善皮肤的弹性；降低血管的通透性，减少水分渗 出。因此具有改善眼部肌肤弹性和对抗水肿的功能，被用于缓解眼袋和黑眼圈。
作为在优选所述的两种不同分子量透明质酸钠复合作用，中分子透明质酸钠在皮肤表层形 成透气膜，锁住水分紧致紧肤；小分子透明质酸钠可渗透皮肤真皮层，在皮肤内部发挥作用，锁住水 分促进皮肤代谢，使皮肤湿润光滑、细腻柔嫩、富有弹性。从而达到紧实丰盈肌肤，减少眼部皱纹， 增加保护屏障。
作为在优选所述的水解大豆蛋白和水解小麦蛋白复配使用在皮肤表面形成保湿性保护膜， 水解大豆蛋白，以诱导元的角色，增加肌肤透明质酸的浓度，以达到高效保湿的效果。水解小麦蛋白 主要氨基酸麦醇溶蛋白和麦谷的蛋白，含有丰富的胱氨酸。它具有保湿、抗氧化作用及柔软细化皮肤， 有特别润肤成分，改善皱纹。两者合作增进皮肤表皮细胞外基质的黏着，保持紧致状态，提高细胞蛋 白质水平，促进胶原蛋白形成，达到协同抗皱效果。
作为在优选所述的作为优选所述的北美金缕梅提取物调节皮脂分泌、舒缓、收敛、抗菌、保 湿、嫩白肌肤；祛眼脬和黑眼圈.可以调节皮脂分泌、具保湿及嫩白。促进淋巴血液循环，可专门克 服早晨眼脬和黑眼圈。具有镇静、安抚的效果，对龟裂、晒伤、粉刺有改善效果。可有效帮助肌肤夜 间的再生能力。去除眼袋、放松以及缓和对於油性肌肤或是过敏的肌肤都有很优异的效果。有舒缓、 收敛、抗菌、抗衰老的效果，因有收敛控油、杀菌的显著疗效。
作为在优选所述的库拉索芦荟提取物主要成分为多糖类、蒽醌类化合物、蛋白质、维生素、 矿物质等。可全面修复人体受损组织，迅速排除体内各种毒素，增强机体免疫力、延缓肌肤衰老。
上述眼霜中，还可以包含防腐剂0.35％。
为了实现上述的第二个目的，本发明采用了以下技术方案：
一种制备上述眼霜的方法，该方法包括以下步骤：
1)将规定量的去离子水、透明质酸、小分子透明质酸钠、尿囊素、丁二醇加入水相反应锅中，开启 搅拌，加热至80～85℃。
2)将聚丙烯酸酯交联聚合物-6、聚二甲基硅氧烷、牛油果树果脂、花生醇/山嵛醇/花生醇葡糖苷聚 合物、环聚二甲基硅氧烷、丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物/异十六烷/聚山梨醇酯-80聚合物、 聚丙烯酰胺/C13-14异链烷烃/月桂醇聚醚-7聚合物加入油相反应锅中，开启搅拌，加热至75℃-80℃， 至完全溶解，搅拌分散均匀。
3)将油相锅中的原料加入到水相锅中，恒温均质5～10分钟，待均质结束后，保温10分钟。
4)开冷却循环水，搅拌降温，待温度降至55～60℃时，将甜菜碱、烟酰胺、甘草黄酮、库拉索芦荟提 取物、北美金缕梅提取物、欧洲七叶树籽提取物、水解大豆蛋白、水解小麦蛋白、乙酰基四肽-5、D- 泛醇加入反应锅中，恒温均质3～5分钟，保温5分钟。
5)继续搅拌冷却至40℃以下，停止搅拌，出料。
附图说明
图1受试者眼部图像示例
具体实施方式
本发明提供的眼霜是以透明质酸钠、小分子透明质酸钠、甜菜碱、烟酰胺、甘草黄酮、库 拉索芦荟提取物、北美金缕梅提取物、七叶树籽提取物、水解大豆蛋白、水解小麦蛋白、乙酰基四肽 -5、D-泛醇为主要活性成分，辅以化妆品常用基质成分保湿剂、增稠剂、防腐剂、植物提取物及水 制成。下面列举一部分具体实施例对本发明进行说明，但并不限制本发明的内容。
实施例1
眼霜：
组成上述眼霜的组分及其百分数含量为：
上述眼霜的制备方法，包括下列步骤：将规定量的去离子水、透明质酸、小分子透明质酸钠、尿 囊素、丁二醇加入水相反应锅中，开启搅拌，加热至80～85℃；将聚丙烯酸酯交联聚合物-6、聚二甲 基硅氧烷、牛油果树果脂、(花生醇、山嵛醇、花生醇葡糖苷)、环聚二甲基硅氧烷、(丙烯酸钠/丙烯 酰二甲基牛磺酸钠共聚物、异十六烷、聚山梨醇酯-80)、(聚丙烯酰胺、C13-14异链烷烃、月桂醇聚 醚-7)加入油相反应锅中，开启搅拌，加热至75～80℃，至完全溶解，搅拌分散均匀；将油相锅中的 原料加入到水相锅中，恒温均质5-10分钟，待均质结束后，保温10分钟；开冷却循环水，搅拌降温， 待温度降至55～60℃时，将甜菜碱、烟酰胺、甘草黄酮、库拉索芦荟提取物、北美金缕梅提取物、欧 洲七叶树籽提取物、水解大豆蛋白、水解小麦蛋白、乙酰基四肽-5、D-泛醇加入反应锅中，恒温均质 3～5分钟，保温5分钟；继续搅拌冷却至40℃以下，停止搅拌，出料。
以上所述仅为本发明的实施例，并非因此限制本发明的专利范围，凡是利用本发明的说明内容所 做的等效变换，或直接间接运用在其他的相关技术领域，均同理包含在本发明的专利保护范围内。
实施例5眼霜效果评价
本实验选择实施例5中提供的眼霜进行临床实验
选取28-55岁150名女性，随机分成3组，每组50人，连续试用本实施例眼霜28天。具体实 施方式为清洁肌肤后，取适量(以泵头瓶按压2-3次)眼霜涂于眼周并轻轻按摩至吸收，早晚各一次。 以观察受试者的祛皱及黑眼圈效果，具体为试用前、使用后的眼部细(皱纹)改善情况和皮肤弹性改 善情况。改善情况分为三个等级：无改善、轻微改善、显著改善。按试用时间阶段进行照片取证，分 别为W0(试用前)、W2(试用2周)、W4(试用4周)。对每位使用者进行定期跟踪调查，采用皮肤 测试仪(意大利Callegari Soft Plus)对肤弹性皮进行监测，每14天为一阶段测试一次，持续使用28 天。
皮肤细纹改善率＝各组皮肤弹性改善人数/各组总人数
皮肤弹性改善率＝各组皮肤弹性改善人数/各组总人数
表1.眼部细纹试验结果
由上表所述可知：三组28-55岁受试人员的总体细纹改善情况良好，眼霜使用普遍存在去细纹效 用，仅少量人员无改善，与个人肤质及吸收代谢情况有关，故试用结果存在差异，可以看出本实施例 眼霜具有很好的去细纹效果。
表2.皮肤弹性试验结果
由上表所述可知，该眼霜普遍有效改善眼部弹性，而且在试验过程中均为发现刺激性及过敏现象。根 据试验结果，可知该眼霜有效淡化、祛除细纹，且温和不刺激。
综上所述，本发明眼霜可有效祛除眼部细纹，改善暗沉、松弛、斑点等肌肤老化现象，延缓 肌肤衰老，回复肌肤弹性。
Claims (10)
1.一种眼霜，其特征在于该眼霜按质量百分比计包括以下组分：
2.根据权利要求1所述的一种眼霜，其特征在于该组合物按质量百分比计包括以下的组分：
3.根据权利要求1所述的一种眼霜，其特征在于该组合物按质量百分比计包括以下的组分：
4.根据权利要求1或2或3所述的一种眼霜，其特征在于所述的乙酰基四肽-5是一种四胜肽，常规浓度为1000ppm，添加使用量在0.5～1％。
5.根据权利要求1或2或3所述的一种眼霜，其特征在于所述的水解大豆蛋白、水解小麦蛋白以1∶2复配使用多重作用修复眼部皮肤弹性。
6.根据权利要求1或2或3所述的一种眼霜，其特征在于所述的透明质酸钠是采用两种不同分子量的透明质酸钠以1∶1.5配合使用。
7.根据权利要求书1或2或3所述的一种眼霜其特征在于所述的北美金缕梅提取物是以水剂进行提取的萃取液，酚类有效物质含量达到31％。
8.根据权利要求1或2或3所述的一种眼霜，其特征在于所述的甘草黄酮中光甘草定含量不小于0.35％。
9.根据权利要求1或2或3所述的一种眼霜，其特征在于所述的欧洲七叶树籽提取物，其有效物质含量达到98％以上。
10.一种制备权利要求1～9任意一项权利要求所述眼霜的方法。其特征在于该方法包括以下步骤：
1)将规定量的去离子水、透明质酸、小分子透明质酸钠、尿囊素、丁二醇加入水相反应锅中，开启搅拌，加热至80～85℃。
2)将聚丙烯酸酯交联聚合物-6、聚二甲基硅氧烷、牛油果树果脂、花生醇/山嵛醇/花生醇葡糖苷聚合物、环聚二甲基硅氧烷、丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物/异十六烷/聚山梨醇酯-80聚合物、聚丙烯酰胺/C13-14异链烷烃/月桂醇聚醚-7聚合物加入油相反应锅中，开启搅拌，加热至75～80℃，至完全溶解，搅拌分散均匀。
3)将油相锅中的原料加入到水相锅中，恒温均质5-10分钟，待均质结束后，保温10分钟。
4)开冷却循环水，搅拌降温，待温度降至55～60℃时，将甜菜碱、烟酰胺、甘草黄酮、库拉索芦荟提取物、北美金缕梅提取物、欧洲七叶树籽提取物、水解大豆蛋白、水解小麦蛋白、乙酰基四肽-5、D-泛醇加入反应锅中，恒温均质3～5分钟，保温5分钟。
5)继续搅拌冷却至40℃以下，停止搅拌，出料。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010015927.8A CN113069393A (zh) | 2020-01-06 | 2020-01-06 | 一种眼霜及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010015927.8A CN113069393A (zh) | 2020-01-06 | 2020-01-06 | 一种眼霜及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113069393A true CN113069393A (zh) | 2021-07-06 |
Family
ID=76608950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010015927.8A Pending CN113069393A (zh) | 2020-01-06 | 2020-01-06 | 一种眼霜及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113069393A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115120532A (zh) * | 2022-08-19 | 2022-09-30 | 厦门海马化妆品有限公司 | 一种护肤膏霜及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107890456A (zh) * | 2017-11-21 | 2018-04-10 | 上海合轩品牌管理有限公司 | 一种眼霜及其制备方法 |
-
2020
- 2020-01-06 CN CN202010015927.8A patent/CN113069393A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107890456A (zh) * | 2017-11-21 | 2018-04-10 | 上海合轩品牌管理有限公司 | 一种眼霜及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| 伍新龙主编: "《青春护照》", 30 September 2003, 广州出版社 * |
| 国产非特殊用途化妆品备案服务平台: "Flora&Folia金缕梅眼凝胶", 《HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/FW.JSP，HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=201812261311143SPQ0&NID=201812261311143SPQ0》 * |
| 国家药品监督管理局: "雅歌布七叶树籽舒缓紧致眼霜", 《HTTPS://WWW.NMPA.GOV.CN/DATASEARCH/SEARCH-INFO.HTML?NMPA=AWQ9NJYXMZIMAXRLBULKPTJJOWJHMZG0NZU5YZK1NZCWMTC1OWNKYZDLZMMWNDQZ，HTTP://CPRP.NMPA.GOV.CN/SFDA/SHOWJSYQACTION.DO》 * |
| 饶蓉蓉著: "《魅力女性形象设计》", 31 July 2019, 民主与建设出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115120532A (zh) * | 2022-08-19 | 2022-09-30 | 厦门海马化妆品有限公司 | 一种护肤膏霜及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107334726B (zh) | 一种祛痘组合物及其制备方法和应用 | |
| CN110448509A (zh) | 一种具有舒敏修复功效的多肽精华液及其制备方法 | |
| CN113786376B (zh) | 一种具有去眼纹功效的眼霜组合物及其制备方法 | |
| CN105232442A (zh) | 一种植物抗氧化氨基酸洁面乳及其制备方法 | |
| CN110772463A (zh) | 眼部肌肤修复组合物及其制备方法和应用 | |
| CN108653129B (zh) | 一种包含天然植物抗敏组合物的皮肤敷料 | |
| CN111973481A (zh) | 一种蓝酮肽修护精华及其制备方法 | |
| CN113332160A (zh) | 一种用于调理毛周角化肌肤的化妆品组合物 | |
| CN110075004B (zh) | 一种复合生物酶医用修复面膜及其制备方法 | |
| CN106333880B (zh) | 一种稀薄乳液基质的爽肤水及其制备方法 | |
| CN113952277A (zh) | 一种微晶肽抗皱面霜及其制备方法 | |
| CN113797143A (zh) | 一种菠萝蛋白酶祛痘精华液及其制备方法 | |
| CN113069393A (zh) | 一种眼霜及其制备方法 | |
| CN113143830A (zh) | 一种含抗初老组合物的眼霜及其制备方法 | |
| CN112402308A (zh) | 一种多效舒缓保湿水及其制备方法 | |
| CN110859758A (zh) | 一种美白抗衰老修复型医用冷敷贴及其制备方法 | |
| CN115154375B (zh) | 一种稳定且具有修护及舒缓功效的清洁组合物 | |
| CN116549307A (zh) | 一种安神舒缓型眼唇卸妆液及其制备方法 | |
| EP3470116A1 (en) | Cosmetic composition for skin and use of a cosmetic composition | |
| CN108354865A (zh) | 一种保湿去皱抗过敏组合物及其制备方法 | |
| CN114642623A (zh) | 一种皮肤抗菌修复功能液及其制备方法和应用 | |
| CN114010551A (zh) | 补水保湿组合物及其应用、化妆水 | |
| KR20140018443A (ko) | 발효 유산균이 함유된 피부질환 예방 및 치료용 조성물 | |
| KR20090003828A (ko) | 탈모방지 및 발모 조성물을 함유하는 헤어토닉 | |
| CN110742819A (zh) | 一种氨基酸洁颜蜜 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210706 |
|
| RJ01 | Rejection of invention patent application after publication |